Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) has cleared the way for use of a new exosome-based cancer detection platform after it published the positive proof-of-concept data.
The data draws the line between healthy individuals and ovarian tumors patients. The findings are based on the amount of exosomes with phosphatidylserine (PS), which is a part of the cell membrane that is key in cell cycle signaling.
In addition, the study on the levels of phosphatidylserine (PS)-positive exosome also allows for differentiation between malignant and benign tumors. Unlike malignant tumors, benign tumors cells don’t spread to other parts of the body. Malignant tumors on the other hand are cancerous and can spread to surrounding tissues, and invade other parts of the body.
Peregrine Pharmaceuticals in July 2016 gave license to University of Texas Southwestern Medical Center’s exosome-based cancer diagnostic technology. The technology tries to examine the diagnostic ability of tumor exosomes, the tiny vesicles or cysts found in tumor cells which the cells released into the blood depending on the level of growth of the tumor. These tumor exosomes have phosphatidylserine embedded on their surface, and the capacity to identify it as well as measure its presence is a potentially detectable identity and perfect tool to recognizing the presence, growth and development of a tumor in a person’s body.
Peregrine is working hard to develop the platform which will help in building a dependable test for further future clinical testing. It is developing a reliable partner as it seeks to development and commercialize the concept, which in its belief offers a unique technique for cancer detection.
Although recent results recorded in the proof of concept research are initial, the finding indicate the crucial diagnostic ability of the platform which can form the basis for pave quick, easy and accurate method of detection of a variety of tumors. Phosphatidylserine (PS) works for a wide range of cancers.
According to Stephen Worsley, the vice president of business development at Peregrine, the exosome-based technology is a very important development owing to the fact that the field is the fastest growing part of the oncology diagnostics market.